Johnson & Johnson (NYSE:JNJ) Holdings Raised by Mitchell & Pahl Private Wealth LLC

Mitchell & Pahl Private Wealth LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,174 shares of the company’s stock after buying an additional 739 shares during the period. Johnson & Johnson makes up 1.2% of Mitchell & Pahl Private Wealth LLC’s portfolio, making the stock its 20th biggest position. Mitchell & Pahl Private Wealth LLC’s holdings in Johnson & Johnson were worth $2,628,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Ballentine Partners LLC lifted its holdings in Johnson & Johnson by 2.6% in the 4th quarter. Ballentine Partners LLC now owns 57,853 shares of the company’s stock valued at $8,367,000 after acquiring an additional 1,461 shares during the last quarter. Martel Wealth Advisors Inc acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $246,000. Culbertson A N & Co. Inc. boosted its holdings in Johnson & Johnson by 0.8% during the fourth quarter. Culbertson A N & Co. Inc. now owns 74,871 shares of the company’s stock worth $10,828,000 after buying an additional 559 shares in the last quarter. ZWJ Investment Counsel Inc. grew its position in Johnson & Johnson by 0.8% in the fourth quarter. ZWJ Investment Counsel Inc. now owns 208,857 shares of the company’s stock worth $30,205,000 after buying an additional 1,760 shares during the last quarter. Finally, Tudor Financial Inc. increased its holdings in shares of Johnson & Johnson by 17.5% in the fourth quarter. Tudor Financial Inc. now owns 6,436 shares of the company’s stock valued at $930,000 after buying an additional 959 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday. Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.9 %

Johnson & Johnson stock opened at $146.58 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $352.91 billion, a PE ratio of 21.21, a PEG ratio of 2.52 and a beta of 0.51. The business’s 50-day simple moving average is $148.10 and its 200-day simple moving average is $156.05.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.29 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.